Correction: DNA methyltransferase inhibitors improve the effect of chemotherapeutic agents in SW48 and HT-29 colorectal cancer cells (PLoS ONE (2014) 9, 3 (e92305) DOI: 10.1371/journal.pone.0092305);DNA methyltransferase inhibitors improve the effect of chemotherapeutic agents in SW48 and HT-29 colorectal cancer cells

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Flis, Sylwia ^a   Gnyszka, Agnieszka ^a   Flis, Krzysztof ^b  

^a NATIONAL MEDICINES INSTITUTE   (Poland)

^b INSTITUTE OF BIOCHEMISTRY AND BIOPHYSICS   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; FLUOROURACIL; OXALIPLATIN; ZEBULARINE; ANTINEOPLASTIC AGENT; AZACITIDINE; CYTIDINE; DECITABINE; DNA (CYTOSINE 5) METHYLTRANSFERASE; ENZYME INHIBITOR; PLATINUM COMPLEX; PYRIMIDIN-2-ONE BETA-RIBOFURANOSIDE;

APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE PROGRESSION; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IC 50; MITOCHONDRIAL MEMBRANE POTENTIAL; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL CYCLE; COLORECTAL NEOPLASMS; DNA DAMAGE; DRUG EFFECTS; PATHOLOGY; PATHOPHYSIOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AZACITIDINE; CELL CYCLE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYTIDINE; DNA DAMAGE; DNA-CYTOSINE METHYLASES; ENZYME INHIBITORS; FLUOROURACIL; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; ORGANOPLATINUM COMPOUNDS;

EID: 84899864306     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106142     Document Type: Erratum

References (39)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Pogribny IP, Beland FA (2013) DNA methylome alterations in chemical carcinogenesis. Cancer Lett 1: 39-45.
3. Crea F, Giovannetti E, Cortesi F, Mey V, Nannizzi S, et al. (2009) Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines. Mol Cancer Ther 8: 1964-1973.
4. Gnyszka A, Jastrzȩbski Z, Flis S (2013) DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer. Anticancer Res 33: 2989-2996.
5. National Cancer Institute website - Cancer Drug Information: FDA Approval for Decitabine. Available: http://www.cancer.gov/cancertopics/druginfo/ fdadecitabine. Accessed: 2014 March 3.
6. Holleran JL, Parise RA, Joseph E, Eiseman JL, Covey JM, et al. (2005) Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine. Clin Cancer Res 15: 3862-3868. (Pubitemid 40685607)
7. Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C (2007) Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 25: 4603-4609. (Pubitemid 350035319)
8. Cowan LA, Talwar S, Yang AS (2010) Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors. Epigenomics 2: 71-86.
9. Cheng JC, Yoo CB, Weisenberger DJ, Chuang J, Wozniak C, et al. (2004) Preferential response of cancer cells to zebularine. Cancer Cell 6: 151-158. (Pubitemid 39485687)
10. Yoo CB, Chuang JC, Byun HM, Egger G, Yang AS, et al. (2008) Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev Res (Phila) 1: 233-240.
11. Gessner PK (1995) Isobolographic analysis of interactions: an update on applications and utility. Toxicology 105: 161-179.
12. Chou TC, Talalay P (1983) Analysis of combined drug effects: A new look at a very old problem. Trends Pharmacol Sci 4: 450-454.
13. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
14. Mahyar-Roemer M, Katsen A, Mestres P, Roemer K (2001) Resveratrol induces colon tumor cell apoptosis independently of p53 and precede by epithelial differentiation, mitochondrial proliferation and membrane potential collapse. Int J Cancer 94: 615-622. (Pubitemid 33035679)
15. Nowsheen S, Yang ES (2012) The intersection between DNA damage response and cell death pathways. Exp Oncol 34: 243-254.
16. Bardhan K, Liu K (2013) Epigenetics and colorectal cancer pathogenesis. Cancers (Basel) 5: 676-713.
17. Issa JP (2000) The epigenetics of colorectal cancer. Ann N Y Acad Sci 910: 140-153.
18. Blinman P, Duric V, Nowak AK, Beale P, Clarke S, et al. (2010) Adjuvant chemotherapy for early colon cancer: what survival benefits make it worthwhile? Eur J Cancer 46: 1800-1807.
19. Chau I, Cunningham D (2006) Adjuvant therapy in colon cancer - what, when and how? Ann Oncol 17: 1347-1359. (Pubitemid 44400373)
20. Hellebrekers DM, Griffioen AW, van Engeland M (2007) Dual targeting of epigenetic therapy in cancer. Biochim Biophys Acta 1775: 76-91. (Pubitemid 44895568)
21. Flis S, Gnyszka A, Misiewicz-Krzemińska I, Spławiń ski J (2009) Decytabine enhances cytotoxicity induced by oxaliplatin and 5-fluorouracil in the colorectal cancer cell line Colo-205. Cancer Cell Int 9: 10. doi:10.1186/1475-2867-9-10.
22. Flotho C, Claus R, Batz C, Schneider M, Sandrock I, et al. (2009) DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 23: 1019-1028.
23. Lee T, Karon M, Momparler RL (1974) Kinetic studies on phosphorylation of 5-azacytidine with the purified uridine-cytidine kinase from calf thymus. Cancer Res 34: 2482-2488.
24. Ben Kasus T, Ben Zvi Z, Marquez VE, Kelley JA, Agbaria R (2005) Metabolic activation of zebularine, a novel DNA methylation inhibitor, in human bladder carcinoma cells. Biochem Pharmacol 70: 121-133. (Pubitemid 40797876)
25. Cheng JC, Weisenberger DJ, Gonzales FA, Liang G, Xu GL, et al. (2004) Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 24: 1270-1278. (Pubitemid 38112188)
26. Lemaire M, Momparler LF, Bernstein ML, Marquez VE, Momparler RL (2005) Enhancement of antineoplastic action of 5-aza-2′-deoxycytidine by zebularine on L1210 leukemia. Anticancer Drugs 16: 301-308. (Pubitemid 40283945)
27. Yoo CB, Cheng JC, Jones PA (2004) Zebularine: a new drug for epigenetic therapy. Biochem Soc Trans 32: 910-912. (Pubitemid 39655501)
28. Goffin J, Eisenhauer E (2002) DNA methyltransferase inhibitors - state of the art. Ann Oncol 13: 1699-1716. (Pubitemid 35439450)
29. Palii S, Van Emburgh B, Sankpal U, Brown K, Robertson K (2008) DNA methylation Inhibitor 5-aza-2′-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol 28: 752-771.
30. Riches LC, Lynch AM, Gooderham NJ (2000) Early events in the mammalian response to DNA double-strand breaks. Mutagenesis 23: 331-339.
31. Kurz EU, Lees-Miller SP (2004) DNA damage-induced activation of ATM and ATM-dependent signaling pathways. DNA Repair 3: 889-900. (Pubitemid 38997931)
32. Toledo LI, Murga M, Fernandez-Capetillo O (2011) Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs. Mol Oncol 5: 368-373.
33. Skladanowski A, Bozko P, Sabisz M (2009) DNA structure and integrity checkpoints during the cell cycle and their role in drug targeting and sensitivity of tumor cells to anticancer treatment. Chem Rev 109: 2951-2973.
34. Roos WP, Kaina B (2013) DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett 332: 237-248.
35. Mossman D, Kim KT, Scott RJ (2010) Demethylation by 5-aza-2′- deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists. BMC Cancer 10: 366.
36. Lind GE, Thorstensen L, Løvig T, Meling GI, Hamelin R, et al. (2004) A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines. Mol Cancer 11: 3-28.
37. Deng G, Peng E, Gum J, Terdiman J, Sleisenger M, et al. (2002) Methylation of hMLH1 promoter correlates with the gene silencing with a region-specific manner in colorectal cancer. Br J Cancer 86: 574-579. (Pubitemid 34185095)
38. ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Cancer Res 61: 2816-2821.
39. Marquez VE, Kelley JA, Agbaria R, Ben-Kasus T, Cheng JC, et al. (2005) Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. Ann N Y Acad Sci 1058: 246-254.